Cholera Vaccines Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Cholera Vaccines Market Trends and Insights

Escalating Multi-Continent Outbreaks

Thirty-three countries reported active cholera outbreaks in December 2024, more than double the historical norm, underscoring shifting epidemiology driven by extreme weather and population displacement ^{[1]World Health Organization, "Multi-country cholera outbreak, external situation report," who.int}. Rising case-fatality ratios in fragile health systems are propelling governments toward pre-emptive vaccination rather than purely reactive campaigns, thereby lifting baseline demand across the cholera vaccines market. Expanded geographic spread into previously cholera-free zones further stretches stockpile requirements, increasing order volumes and sustaining commercial growth. Health agencies are now forecasting vaccine needs on a multi-year basis, giving manufacturers stronger demand visibility that underpins capacity investments. Elevated outbreak frequency therefore exerts the single largest positive influence on the market outlook.

Expanded Gavi OCV Stockpile Funding

Gavi’s pledge to supply 230 million doses to 31 countries—and its record 96 million-dose shipment over the past two years—marks the largest coordinated cholera vaccination effort to date. The African Vaccine Manufacturing Accelerator allocates USD 1.2 billion to regional production, with France contributing EUR 10 million, signaling long-term procurement security for producers ^{[2]Gavi, " Protecting more children, against more diseases, faster than ever before: Gavi, the Vaccine Alliance unveils plans for next 5-year period, " gavi.org}. Preventive campaigns need three to four times more doses than reactive drives, directly scaling the cholera vaccines market. Guaranteed offtake contracts de-risk capital spending, accelerate line expansions, and encourage technology transfer to Africa and Asia, ultimately broadening supply resilience. Together these funding mechanisms inject consistent volume growth into the forecast period.

Climate-Linked Coastal Flooding in Endemic Megacities

Meteorological data connect heavier rainfall, warmer seas, and inadequate sanitation to Vibrio cholerae proliferation in coastal megacities. ^{[3]Center for Disease Control and Prevention, "A summary of health effects, resources, and adaptation examples from health departments funded by CDC’s Climate and Health Program," cdc.gov} Flood events precede cholera spikes by 2-3 weeks, providing a predictive window for vaccination. Urban centers with more than 5 million inhabitants face compounding climate and infrastructure risk, prompting ministries of health to budget seasonal vaccine buys. This driver sustains double-digit demand growth in Asia-Pacific and Sub-Saharan Africa across the forecast horizon.  

Live Single-Dose Approvals in Travel Clinics

The FDA-approved live oral vaccine Vaxchora shows 90.3% efficacy after 10 days, eliminating the compliance gap inherent in two-dose regimens. Travel clinics favor the convenience of single-visit dosing, and insurers in North America and Europe reimburse the premium, creating a lucrative private-sector niche within the cholera vaccines market. Strong traveler uptake has triggered additional regulatory filings in Europe and Asia, broadening revenue streams that are independent of humanitarian cycles. 

Two-Dose Compliance Gaps

Second-dose completion rates dip to 64-73% in mass campaigns, limiting population immunity and prompting calls for simpler schedules. Barriers include migration, competing livelihoods, and inadequate community messaging. Although alternative delivery models—such as self-administration or extended intervals—improve uptake, each adds logistical complexity. The constraint reduces effective coverage and tempers near-term growth projections, catalyzing investment in single-dose approaches that can close the compliance gap.  

OMV Component Bottlenecks

Outer membrane vesicle-based candidates promise broader antigenic coverage but require specialized processing to control endotoxicity, and global capacity is concentrated among a handful of Asian suppliers. Any production hiccup reverberates through the entire cholera vaccines market, as seen in the 2024 stock-out. Capital-heavy upgrades and stringent quality checks lengthen scale-up timelines, restraining supply even as demand climbs.  

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Vaccine Type: Killed Vaccines Maintain Dominance Amid Innovation

Killed Oral O1 and O139 vaccines generated 74.02% of the cholera vaccines market in 2025, a position secured by decades of field evidence and WHO prequalification. The segment accounted for the largest cholera vaccines market size portion at USD 76.2 million in 2025. Capacity gains from EuBiologics’ Euvichol-S line alone will add 50 million doses annually, strengthening supply resilience. However, recombinant B-subunit enhancements are unlocking higher pediatric efficacy and, at 10.98% CAGR, are the fastest-advancing sub-segment through 2031.  

Live-attenuated candidates, though still niche, match the industry’s pivot toward single-dose ease. Vaxchora exemplifies the commercial potential: its 90.3% short-term efficacy and 79.5% at three months position it as the traveler’s vaccine of choice. Development pipelines include edible rice-based formulations and mRNA prototypes that could bypass cold chains, underscoring an innovation race likely to re-shape competitive dynamics after 2027. 

By Product: Dukoral’s Legacy vs. Vaxchora’s Momentum

Dukoral held 38.35% of revenue in 2025, buoyed by long-standing WHO approval and entrenched travel-clinic usage. Yet Vaxchora is set to outpace every other brand at 10.96% CAGR through 2031, carving a profitable lane in single-dose convenience. 

Public-sector stalwarts Euvichol-Plus and Shanchol continue to dominate humanitarian procurement on price, reinforcing their role in large-scale preventive programs funded by Gavi. The “Others” category—housing regional candidates and pipeline products—could disrupt share splits once late-stage trials read out post-2027.  

By Distribution Channel: Private Sector Acceleration

Public tenders still delivered 71.05% of the cholera vaccines market size in 2025, underpinned by UNICEF and Gavi contracts that absorb volume at cost-plus pricing. Private sales, though smaller, are expanding at 11.14% CAGR, led by travel-clinic chains and corporate occupational-health programs in North America and Europe. 

The dual-channel structure enables cross-subsidization: higher private-sector prices offset low margins in humanitarian supply, supporting manufacturer profitability and R&D spend.  

Geography Analysis

North America commanded 37.21% of 2025 revenue, propelled by Vaxchora’s premium pricing and a mature travel-health infrastructure that guarantees consistent uptake even during global shortages. Corporate duty-of-care policies further institutionalize demand, ensuring that private-sector volumes remain insulated from humanitarian stockpile dynamics.  

Asia-Pacific is the fastest-growing territory, advancing at an 11.32% CAGR through 2031 as India, Bangladesh, and Vietnam shift to routine pre-monsoon vaccination. National demonstration projects have validated cost-effectiveness, attracting multilateral financing that secures multiyear procurement. Emerging manufacturing hubs in India will shorten supply chains and curb freight costs, reinforcing regional self-sufficiency.  

Europe maintains a dual role as both buyer and manufacturer. Robust regulatory frameworks, coupled with Sanofi’s EUR 1 billion investment in flexible bioproduction, support future mRNA-based cholera candidates. Meanwhile, development assistance from France and the EU is channeling technology transfer to Africa, reflecting a policy stance that sees vaccine self-reliance as a pillar of global health security.  

Regulatory Landscape

Regulation in the cholera vaccines market is anchored by WHO prequalification (PQ), which serves as the primary compliance gateway for international procurement and humanitarian tenders. A key reference point is WHO prequalification of EuBiologics' Euvichol-S in April 2024, which expanded the pool of PQ-compliant oral cholera vaccines used by global procurers and national programs.

In high-income markets, country and regional regulators shape travel-clinic access and labeling requirements. In the United States, Vaxchora remains the only FDA-approved cholera vaccine for people aged 2 through 64 years, and FDA actions such as the June 2024 supplement approval for labeling updates (including room-temperature storage language) highlight the importance of stability and logistics claims for distribution. In Europe, Vaxchora is regulated via centralized EMA authorization, with a renewal recorded in January 2025, supporting standardized access and pharmacovigilance expectations across member states.

Market Opportunities and Future Outlook

A near-term whitespace is reopening for mass preventive vaccination after supply constraints pushed many countries toward reactive-only use. In February 2026, WHO, UNICEF, and Gavi announced that preventive cholera vaccination campaigns resumed for the first time in more than three years as global OCV supply reached a critical milestone. This shift expands addressable volumes because preventive campaigns require materially more doses than outbreak response, giving ministries of health and procurement agencies more consistent multi-year planning.

On the supply side, opportunities cluster around expanding WHO PQ-compliant capacity and diversifying manufacturing geographies to reduce single-supplier risk. Annual global supply of oral cholera vaccines increased from about 35 million doses in 2022 to nearly 70 million doses in 2025, and capacity additions are being linked to PQ and export-readiness milestones, including EuBiologics securing WHO PQ for a finished-product manufacturing line for Euvichol-S at its second plant (June 2025). Pipeline and entrant activity also adds supply headroom for new tenders: Bharat Biotech reported successful Phase III results for Hillchol (May 2025), citing stated capacity up to 200 million doses across its facilities, positioning it for participation once global procurement requirements (including WHO PQ) are met.